Friday, 15 Dec 2017

TNF inhibitor

Datesort ascending Type Title Save
18 Oct 2016 Social TNF inhibitor use in 16 renal transplant pts w/ good efficacy, no decline in GFR x2yrs, but 1/2 had Serious infxns https://t.co/2UHyaiVOpM
18 Oct 2016 News Inflectra Biosimilar Ships in Late November 2016
06 Oct 2016 Social IRAK3 rs11541076 polymorphism yields 33% increase odds of response to TNFi. NLRP3 rs461266 has 25% fewer responses. https://t.co/qIuf7dJKU3
05 Oct 2016 News Infection Rates Stable in JIA With Anti-TNF Therapy
03 Oct 2016 Social Mayo study of incident Sarcoidosis shows 3 fold higher risk of Venous thrombosis & 4 fold risk of pulm embolism. https://t.co/3Gv1bAumBf
26 Sep 2016 News FDA Approves New Amgen Biosimilar for Adalimumab
18 Sep 2016 Social TNFi induced Psoriasis can be treated w/ TNFi D/C, another TNFi (48-85% recurrence) or Stelara. Good short review https://t.co/t2Hb7kA4ru
16 Sep 2016 Social Humira price has increased 6% q 3month for 3 yrs - now $15 billion/yr in USA - what wil happen when biosimilars hi https://t.co/gmX8TeD4ll
31 Aug 2016 News Another Biosimilar Approval - Etanercep-szzs by Novartis
30 Aug 2016 Social Drug retention rates are same between elderly and younger RA pts on TNFi. D/C for AE in old and efficacy in young. https://t.co/ZPXlXvVpTS
29 Aug 2016 Slide of the day Non-Tuberculous Mycobacterial Infection are Common with TNF Inhibitors
18 Aug 2016 News Remicade Patent Infringements Denied: Opens Door for New Biosimilars
09 Aug 2016 News Etanercept May Lower Alzheimers Risk in Rheumatoid Arthritis
08 Aug 2016 Slide of the day Tuberculosis Risk Reduction Measures
27 Jul 2016 News Long-Term Safety of Adalimumab Reviewed
14 Jul 2016 News Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee
13 Jul 2016 News FDA Arthritis Advisory Committee Recommends Approval of Adalimumab Biosimilar
01 Jul 2016 News Adalimumab Approved for Uveitis
28 Jun 2016 News Cancer Risk Lower with TNF inhibitors in Rheumatoid Arthritis
27 Jun 2016 Social Humira sales projected to increase in next 3 years; others may decline https://t.co/x2zj7dtYdC https://t.co/vHjJlQI6n2